Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation

JAMA

Volumn 296, Issue 4, 2006, Pages 397-402

  Hron, Gregor ^a   Kollars, Marietta ^a   Binder, Bernd R ^a   Eichinger, Sabine ^a   Kyrle, Paul A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTIVITAMIN K; HEPARIN; LUPUS ANTICOAGULANT; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CANCER; CARDIOVASCULAR RISK; CLINICAL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG WITHDRAWAL; ENZYME ANALYSIS; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PATIENT IDENTIFICATION; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RECURRENT DISEASE; UNIVERSITY HOSPITAL; VENOUS THROMBOEMBOLISM;

EID: 33746453363     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.4.397     Document Type: Article

References (24)

1. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005;365:1163-1174.
2. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
3. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458-462.
4. Kearon C. Risk Factors for Recurrent Venous Thromboembolism and Their Implications for Treatment: Hematology. Washington, DC: American Society of Hematology; 2004:445-449.
5. Mann KG. Thrombin formation. Chest. 2003;124(3 suppl):4S-10S.
6. Dargaud Y, Beguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost. 2005;93:475-480.
7. Rotteveel RC, Roozendaal KJ, Eijsman L, Hemker HC. The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost. 1993;70:959-962.
8. Wielders S, Mukherjee M, Michiels J, et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost. 1997;77:629-636.
9. Curvers J, Thomassen MC, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost. 2002;88:5-11.
10. Kyrle PA, Mannhalter C, Beguin S, et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol. 1998;18:1287-1291.
11. Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost. 2005;3:2497-2505.
12. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558-2563.
13. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA. 1990;263:2753-2759.
14. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
15. Eichinger S, Weltermann A, Mannhalter C, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med. 2002;162:2357-2360.
16. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14-17.
17. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-462.
18. Weltermann A, Eichinger S, Bialonczyk C, et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost. 2003;1:28-32.
19. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Ridker PM. Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes. J Thromb Haemost. 2004;2:1034-1037.
22. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:287S-310S.
23. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med. 2001;161:1443-1447.
24. Duchemin J, Pittet JL, Tartary M, et al. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost. 1994;71:331-338.